Skip to main content

For Sponsors

FIH in Latin America + expansion in Miami

The integrated Americas model: run first-in-human in Latin America via bioaccess®, expand at our GCSA-certified Miami site — coordinated through one team and one BD contact.

Why sponsors split FIH and expansion geographically

First-in-human studies and later-phase expansion cohorts place different demands on a trial operation. FIH needs specialized Phase 1 units, intensive safety monitoring, and rapid protocol iteration. Expansion needs broad enrollment, diverse patient populations, and pivotal-trial infrastructure.

Sponsors have long run these phases in different geographies to match each phase to the setting where it executes best — FIH where specialized units and startup speed are strongest, expansion where the regulatory and enrollment profile fits the pivotal program.

The friction has always been coordination: two vendors, two contracts, two study-management teams, and knowledge lost in the handoff between phases. The integrated Americas model removes that friction by running both phases under one coordinated team.

Phase 1 — Latin America

The LATAM FIH case

bioaccess®, our sister organization, is a first-in-human CRO operating across the Americas — 50+ delivered FIH programs since 2010, with 15+ years of operating experience in the region.

Latin America offers experienced Phase 1 units, competitive cost structures, and startup timelines that keep early-phase programs moving — with regulatory pathways built for early-phase research.

Expansion — Miami

Why Miami for expansion

When the program moves to expansion, Amavita Research's Miami site brings the profile a pivotal program needs: GCSA-certified (recertified May 13, 2026, valid to Feb 28, 2027), Dr. William W. O'Neill, a senior principal investigator and interventional cardiologist with a structural-heart (TAVR) research background, and a diverse enrollment population — natively aligned with FDA Diversity Action Plan expectations for Phase 3 trials.

Our dedicated cardiovascular ambulatory surgery center supports interventional and device protocols in a controlled outpatient setting, and our PIs recruit from a continuously-enrolling cardiology practice — not a referral network.

How the integrated model works

Single BD contact

Julio G. Martinez-Clark, CEO — julio@amavita.health — is the first touch, CDA, and NDA contact for both the FIH and expansion phases.

Coordinated feasibility & contracting

Feasibility and contracting run in parallel across both geographies — one process, not two vendor negotiations.

One study-management team

A single team carries the program from FIH through expansion — no knowledge lost in a vendor handoff between phases.

FAQ

Questions about the integrated model

Next step

Talk to Amavita Research about your FIH program

One BD contact. Prompt response. FIH in Latin America, expansion in Miami — coordinated as one program.